Eyenovia, Inc.

( )
EYEN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
ABBVAbbVie, Inc. -2.14%90.691.9%$1170.57m
BMYBristol-Myers Squibb Co. 0.97%60.301.0%$1022.03m
JNJJohnson & Johnson -1.08%147.140.7%$983.50m
PFEPfizer Inc. -7.12%35.470.9%$876.73m
MRKMerck & Co., Inc. -1.44%79.560.7%$813.33m
LLYEli Lilly & Co. -0.30%152.491.1%$516.14m
AZNAstraZeneca Plc 1.13%55.221.2%$288.18m
NVSNovartis AG -0.88%86.660.2%$150.52m
GSKGlaxoSmithKline Plc -0.12%41.870.2%$136.22m
NVONovo Nordisk A/S -0.30%65.740.1%$92.44m
SNYSanofi 0.77%49.490.2%$76.06m
RGENRepligen Corp. -0.78%129.967.1%$69.85m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.93%64.300.0%$50.28m
TPTXTurning Point Therapeutics, Inc. -1.44%68.250.0%$41.29m
APLSApellis Pharmaceuticals, Inc. 0.95%34.010.0%$35.49m

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.